News

Cytokine has initiated the phase I study of CPSI-2364, its orally active, smallmolecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. CPSI-2364 is a chemically-modified form

Nycomed has submitted a New Drug Application (NDA) to the FDA for Daxas, as a once-daily oral treatment for patients with symptomatic COPD. The NDA submission is based

Stem (SCT) has received a No Objection Letter (NOL) from Health Canada for the modified Regenesis protocol using NTx-265, for a phase IIb clinical trial for the treatment

Boehringer Ingelheim has declared results from the Arten trial at the 5th International AIDS Society conference in Cape Town, South Africa. The study demonstrated non-inferiority regarding efficacy between

Roche has provided the results from the international phase III study NO16968 (Xeloxa), investigating oral Xeloda in combination with intravenous oxaliplatin (Xelox) immediately after surgery. The study showed

Generex has published the results from preclinical studies, demonstrating the anti-cancer activity of a novel Ii-Key/HPV immunotherapeutic vaccine. The immunotherapeutic vaccine for HPV-induced cancers make use of the

Merck & Co.’s integrase inhibitor, Isentress (raltegravir), was as effective as efavirenz at maintaining viral load suppression to undetectable levels and improving CD4 counts in previously untreated patients

Human Genome (HGS) and GlaxoSmithKline (GSK) has reported that Benlysta (belimumab) met its primary endpoint by achieving a significant improvement in patient response rate versus placebo in BLISS-52.

Merck & Co. has reported non-GAAP earnings per share (EPS) for the quarter of $0.83, which excludes $0.09 of restructuring charges and merger-related expenses. Second-quarter GAAP EPS was